Zealand Pharma | Evaluate

Key data catalysts for the industry’s small players

Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.

Combining forces in metabolic disorders

Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.

April 01, 2021

US FDA approval tracker: March 2021

March 01, 2021

Go or no go? A delayed decision on Evrenzo

March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.

June 21, 2018

Beta Bionics brings machine learning to insulin delivery

Can a device control a patient’s blood sugar based on bodyweight alone?

November 23, 2016

Novo and Sanofi cut thinner slice of the diabetes pie

May 26, 2016

The adcom vote is an equaliser, but Novo has already beaten Sanofi

April 28, 2016

Semaglutide heart data spice up once-weekly GLP-1 race

February 16, 2016

Zealand plays catch-up with Shire in short bowel syndrome

February 05, 2016

Upcoming events – Bayer’s lung cancer effort and Apricus and Zealand try again

July 29, 2015

Sanofi’s positive result in LixiLan-O comes a little too late

Load More